How have MACK shares performed in 2024?

Merrimack Pharmaceuticals' stock was trading at $13.41 at the beginning of the year. Since then, MACK stock has increased by 9.8% and is now trading at $14.72. View the best growth stocks for 2024 here .

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MACK earnings forecast .

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN) , Inovio Pharmaceuticals (INO) , Rite Aid (RAD) , Anavex Life Sciences (AVXL) , Gilead Sciences (GILD) , Novavax (NVAX) , Exelixis (EXEL) , Amicus Therapeutics (FOLD) , Bausch Health Companies (BHC) and Verastem (VSTM) .

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free MACK Stock Alerts

$14.72

+0.04 (+0.27%)

(As of 04/19/2024 ET)

Compare

Today's Range: $14.68
▼
$14.73
50-Day Range: $13.99
▼
$15.00
52-Week Range: $11.53
▼
$15.89

Volume: 76,084 shs
Average Volume: 111,833 shs
Market Capitalization: $213.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Merrimack Pharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

MACK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MACK Stock News Headlines

April 13, 2024 | americanbankingnews.com

Merrimack Pharmaceuticals (NASDAQ:MACK) and Seelos Therapeutics (NASDAQ:SEEL) Critical Comparison

April 3, 2024 | finance.yahoo.com

Diagonal starts up with $128M to make better ‘activator’ antibody drugs

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 27, 2024 | businesswire.com

Merrimack Receives $225 Million Milestone Payment from Ipsen

March 8, 2024 | msn.com

Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts

March 8, 2024 | investorplace.com

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023

March 7, 2024 | businesswire.com

Merrimack Reports Full Year 2023 Financial Results

March 4, 2024 | finance.yahoo.com

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 22, 2024 | benzinga.com

Merrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, Predictions

February 17, 2024 | finance.yahoo.com

MACK Mar 2024 14.000 put

February 17, 2024 | finance.yahoo.com

MACK Mar 2024 4.000 put

February 15, 2024 | markets.businessinsider.com

OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

February 14, 2024 | finance.yahoo.com

MACK Feb 2024 16.000 put

February 14, 2024 | finance.yahoo.com

Ipsen drug approved by FDA for early pancreatic cancer

February 13, 2024 | msn.com

The S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cuts

February 13, 2024 | marketwatch.com

Merrimack Pharmaceuticals to Hold Meeting on Corporate Dissolution

February 13, 2024 | finance.yahoo.com

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

February 13, 2024 | businesswire.com

December 12, 2023 | msn.com

$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying

December 10, 2023 | finance.yahoo.com

We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

November 10, 2023 | morningstar.com

Merrimack Pharmaceuticals Inc MACK

November 2, 2023 | finance.yahoo.com

Merrimack Reports Third Quarter 2023 Financial Results

October 24, 2023 | stockhouse.com

Onconova Expands Leadership Team with Two Key Appointments

October 20, 2023 | theglobeandmail.com

The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

August 15, 2023 | finance.yahoo.com

Western Standard LLC Boosts Stake in Merrimack Pharmaceuticals Inc

August 13, 2023 | insidermonkey.com

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript

See More Headlines

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:MACK
CUSIP: 59032810
CIK: 1274792
Web: www.merrimackpharma.com
Phone: 617-720-8606
Fax: 617-491-1386
Employees: 426
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): ($0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -6.24%
Return on Assets: -6.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 43.50
Quick Ratio: 43.50

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 11.24

Miscellaneous

Outstanding Shares: 14,530,000
Free Float: 10,337,000
Market Cap: $213.88 million
Optionable: Optionable
Beta: 1.43

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Gary L. Crocker M.B.A. (Age 72)
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Comp: $76k
Dr. Ulrik B. Nielsen Ph.D. (Age 52)
Co-Founder & Independent Director
Comp: $72.5k
Dr. Anthony J. Sinskey Ph.D. (Age 84)
Sc.D., Co-Founder and Scientific Advisor
Comp: $4.25k
Mr. Timothy R. Surgenor (Age 64)
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MACK Stock Analysis - Frequently Asked Questions

How have MACK shares performed in 2024?: Merrimack Pharmaceuticals' stock was trading at $13.41 at the beginning of the year. Since then, MACK stock has increased by 9.8% and is now trading at $14.72.
View the best growth stocks for 2024 here.
When is Merrimack Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MACK earnings forecast.
How were Merrimack Pharmaceuticals' earnings last quarter?: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.
When did Merrimack Pharmaceuticals' stock split?: Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).
How do I buy shares of Merrimack Pharmaceuticals?: Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MACK) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial